Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- visual loss
- macrocephaly and hydrocephalus
- growth failure
Outros fatores diagnósticos
- symptoms of hypogonadotropic hypogonadism (amenorrhea, erectile dysfunction)
- headache
- symptoms of intracranial hypertension (nausea, vomiting, decreased sensorium, diplopia)
- galactorrhea
- optic atrophy
- polyuria/polydipsia
Fatores de risco
- age 5 to 14 years
- age 50 to 70 years
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- ophthalmologic evaluation; computerized visual-field examination
- MRI brain (contrast-enhanced)
- CT brain (contrast-enhanced)
- serum prolactin
- serum growth hormone (GH)
- serum insulin-like growth factor 1 (IGF-1)
- serum insulin-like growth factor binding protein-3 (IGFBP-3)
- provocative growth hormone (GH) tests
- serum luteinizing hormone
- serum follicle-stimulating hormone
- morning serum testosterone
- serum thyroid-stimulating hormone and T3/T4
- morning serum cortisol and adrenocorticotropic hormone (ACTH)
- serum electrolytes
- urine and serum osmolality
- urine specific gravity
- plain x-rays for bone age
Investigações a serem consideradas
- tissue histology
Algoritmo de tratamento
at initial treatment
post initial treatment
Colaboradores
Autores
Marc C. Chamberlain, MD

Chief
Division of Neuro-Oncology
Department of Neurology and Neurological Surgery
University of Washington
Seattle Cancer Care Alliance
Seattle
WA
Declarações
MCC declares that he has no competing interests.
Agradecimentos
Dr Marc C. Chamberlain would like to gratefully acknowledge Dr Daniel L. Silbergeld, a previous contributor to this topic.
Declarações
DLS declares that he has no competing interests.
Revisores
Larry Junck, MD
Professor of Neurology
Department of Neurology
University of Michigan
Ann Arbor
MI
Declarações
LJ declares that he has no competing interests.
Jeff Raizer, MD
Associate Professor of Neurology
Director of Medical Neuro-Oncology
Northwestern University
Chicago
IL
Declarações
JR declares that he has no competing interests.
Ramez Kirollos, MBChB, FRCS(Ed), FRCS(Eng), MD, FRCS(SN)
Consultant Neurosurgeon
Addenbrooke's Hospital
Cambridge University Hospitals NHS Foundation Trust
Cambridge
UK
Declarações
RK declares that he has no competing interests.
Keyoumars Ashkan, BA, BSc, MB BCh, MRCP, FRCS, FRCPS, FRCS(SN), MD
Consultant Neurosurgeon and Lead of Neuro-Oncology
King's College Hospital
London
UK
Declarações
KA declares that he has no competing interests.
Edwin S. Kulubya Jr., MD, MBA
Neurosurgical Research Fellow
UC Davis Medical Center
Sacramento
CA
Declarações
EK declares that he has no competing interests.
Créditos aos pareceristas
Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.
Declarações
As afiliações e declarações dos pareceristas referem--se ao momento da revisão.
Referências
Principais artigos
Garre ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr. 2007 Aug;19(4):471-9. Resumo
Puget S, Garnett M, Wray A, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. 2007 Jan;106(1 suppl):3-12. Resumo
Minniti G, Saran F, Traish D, et al. Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol. 2007 Jan;82(1):90-5. Resumo
Dekkers OM, Biermasz NR, Smit JW, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol. 2006 Mar;154(3):483-9.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

Diagnósticos diferenciais
- Pituitary adenoma
- Diaphragmatic meningioma
- Chiasmatic epidermoid
Mais Diagnósticos diferenciaisConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal